Phase 1 Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People (male or female) who have been diagnosed with DCIS or LCIS (non-invasive breast conditions) found through a core biopsy.
- The breast lesion must be a single area measuring at least 1 cm and no more than 5 cm, seen on imaging such as a mammogram, MRI, or ultrasound, with no sign of invasive cancer on biopsy and no suspicious lymph nodes found on ultrasound.
- People aged 18 or older who are able to give informed consent and agree to follow the study requirements.
- People who are generally well enough to take part, as assessed by the trial investigator using a standard health scale (ECOG score of 0 or 1).
- People whose recent blood test results (taken within 72 hours before Day 0) meet specific levels for white blood cells, red blood cells, platelets, kidney function, and liver function (confirm with trial site for exact values).
- People who are not pregnant, confirmed by a pregnancy test (urine or blood) if there is any possibility of pregnancy.
- People who are able to become pregnant, and their partners, must agree to use effective non-hormonal contraception during treatment and for 165 days after the last dose of the study drug.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with a serious medical or psychiatric condition that, in the investigator's opinion, could put them at risk or interfere with the study.
- People who need to take corticosteroids (such as prednisone) at a dose of 10 mg or more per day, though inhaled steroids are generally acceptable.
- People who need hormonal contraception (such as the pill, implant, injection, vaginal ring, skin patch, or hormonal IUD), or who take certain medications that interact with specific liver enzymes in a way that may affect the study drug (confirm with trial site).
- People with a history of, or currently active, autoimmune diseases that the investigator considers to pose a significant ongoing risk — though conditions such as vitiligo, lichen planus, and well-controlled thyroid disorders are generally not excluded.
- People who have previously had a bone marrow transplant or have a history of oral Graft Versus Host Disease (a complication where donor cells affect the recipient's body).
- People with an active infection that requires treatment throughout the body, unless the investigator considers it not clinically significant.
- People with active or uncontrolled Hepatitis B, Hepatitis C, or HIV that has progressed to AIDS-related illness.
- People with a known history of Hepatitis B (based on a specific blood marker) or a known history of active Hepatitis C infection.
- People whose heart tracing (ECG) shows a prolonged QTc interval of more than 480 milliseconds, though some medications associated with this risk may still be allowed at the investigator's discretion.
- People with a history of certain bowel or abdominal conditions — such as acute diverticulitis, abdominal abscess, bowel blockage, or abdominal cancer spread — that the investigator considers to still pose an active risk of bowel perforation.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sasha Stanton, MD, PhD, Providence Health & Services
Phone: 503-215-1979
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of CAN1012
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.